Core Insights - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [3][4] - The company's lead drug candidate, GT-02287, is being evaluated for the treatment of Parkinson's disease, showing favorable safety and tolerability in a Phase 1 study [3][4] - CEO Gene Mack will present at two upcoming investor conferences, providing opportunities for investors to engage with management [1][6] Company Overview - Gain Therapeutics specializes in discovering and developing allosteric therapies, utilizing its advanced Magellan™ platform to accelerate drug discovery [3][4] - The company aims to unlock novel treatments for challenging disorders, including neurodegenerative diseases and rare genetic disorders [4] Upcoming Events - Gene Mack will present at the BIO CEO & Investor Conference on February 11, 2025, at 1:15 PM ET [1][6] - A virtual corporate presentation will take place at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 10:40 AM ET [6]
Gain Therapeutics To Participate in Upcoming Investor Conferences